Table of Contents Table of Contents
Dia 1 Next Page
Information
Show Menu
Dia 1 Next Page

 


1. Intro_DBN16.pdf 		1
Welcome toAdvanced Skills for Modern Radiation Therapy- RTT only - 		1
Slide Number 2 		2
Slide Number 3 		3
Slide Number 4 		4
Slide Number 5 		5
Slide Number 6 		6
Slide Number 7 		7
Slide Number 8 		8
Slide Number 9 		9
Slide Number 10 		10
Slide Number 11 		11
Slide Number 12 		12
Slide Number 13 		13
Slide Number 14 		14
Slide Number 15 		15
Slide Number 16 		16
Slide Number 17 		17
Slide Number 18 		18
Slide Number 19 		19
Slide Number 20 		20
Slide Number 21 		21
3. Patient preparation and positioning_MKA 		22
Slide Number 1 		22
Patient Preparation and Positioning 		23
Slide Number 3 		24
Slide Number 4 		25
Expectation management 		26
Slide Number 6 		27
Slide Number 7 		28
Slide Number 8 		29
Pelvic patients: dietary protocol 		30
Slide Number 10 		31
Prostate patients 		32
Slide Number 12 		33
Slide Number 13 		34
Slide Number 14 		35
Slide Number 15 		36
Slide Number 16 		37
Slide Number 17 		38
Creating unfortunate differences 		39
Example 1: Look for differences.. 		40
Slide Number 20 		41
Slide Number 21 		42
Slide Number 22 		43
Slide Number 25 		44
Practical session 		45
Slide Number 27 		46
Slide Number 28 		47
Slide Number 29 		48
Slide Number 30 		49
Slide Number 31 		50
Slide Number 32 		51
Slide Number 33 		52
Rectum patients 		53
Slide Number 35 		54
Essential: education & compliance 		55
Slide Number 37 		56
Slide Number 38 		57
Slide Number 39 		58
4. Josipovic Pre-treatment imaging 		59
5. Delineation_SR 		119
Slide Number 1 		119
Which are the 3 weakest points in our modern radiotherapy treatment chain? 		120
Learning outcomes 		121
Delineation: one of the links in the treatment chain 		122
Why is delineation important? 		123
Do we need to improve? 		124
How can we answer that need ? 		125
Did you know before this course that ESTRO provides a platform for hands on exercises on contouring? 		126
Inter-observer variability in contouring 		127
Does heterogeneity in RT matters? 		128
Hypoxia radioresistance 		129
Slide Number 12 		130
Slide Number 13 		131
Slide Number 14 		132
How to improve? 		133
ICRU Guidelines (ICRU50): volume definition 		134
Tumor Gross Volume: GTV 		135
Tumor Gross Volume: GTV 		136
Tumor Gross Volume: GTV 		137
PET scans in delineation of lung cancer 		138
Tumor Gross Volume: GTV 		139
Clinical Target Volume: CTV 		140
CTV 		141
Clinical Target Volume: CTV 		142
GTV and CTV 		143
Planning Target Volume: PTV 		144
PTV 		145
Irradiated Volume and Treated Volume: IRV and TV 		146
ICRU 50 		147
ICRU 62 (in addition to ICRU 50) 		148
Set up Margin: SM 		149
What is the definition of the ITV? 		150
What is the definition of the PTV? 		151
Slide Number 34 		152
Slide Number 35 		153
Contouring Guidelines 		154
Contouring Guidelines 		155
Contouring Guidelines 		156
Contouring guidelines 		157
Contouring guidelines 		158
ESTRO guidelines 		159
Take home messages:- Inter observer variability in contouring can translate in a systematic error- Need for a common language: ICRU - Need for delineation guidelines- Need for teaching in contouring 		160
Thank you for you attention 		161
Which are the 3 weakest points in our modern radiotherapy treatment chain? 		162
6. Forde_OAR Delineation 2016 		163
11. Josipovic Image registration 		220
14. Josipovic Motion management 		261
15. Forde_Planning 2016 		301
16. In-room imaging modalities_MK def 2003 		356
Slide Number 1 		356
Content of the presentation 		357
At the start of treatment 		358
In fact…it’s just a snapshot 		359
Why do we need imaging on the linac? 		360
Imaging modalities 		361
Ultrasound systems 		362
More recent developments 		363
Ultrasound system 		364
Electromagnetic tracking 		365
Electromagnetic tracking 		366
Electromagnetic tracking (GPS) 		367
Portal Imaging - physics 		368
Goals of PortaI Imaging 		369
Technical aspects of EPIDs 		370
Examples of portal images (open field) 		371
EPID – field images 		372
Electronic Portal Imaging 		373
2D kV imaging 		374
kV source moutend on linac 		375
kV imaging: Cyberknife 		376
Slide Number 22 		377
Exac Trac® IGRT system 		378
OBI kV imaging 		379
kV imaging 		380
Cone beam CT 		381
CBCT Acquisition 		382
How does it work? 		383
Image registration: Defining the ROI 		384
Image registration: Defining the ROI 		385
Image registration 		386
Image registration: bony anatomy 		387
Image registration: fiducial markers 		388
CBCT imaging 		389
MV-(CB)CT 		390
MV-CT 		391
Videosystems 		392
Exac trac infrared 		393
Surface scanning 		394
Infra red systems 		395
Slide Number 41 		396
Integrating MRI functionality with external beam radiotherapy 		397
Gantry design MRL: (MRI-Linac) 		398
MRIdian: MR Cobalt 		399
MR linac 		400
How accurate should the delivery be? 		401
17. Clinical rationale for IGRT_Jose Lopez_clean 		402
Slide Number 1 		402
Learning Objectives (IGRT) 		403
Wikipedia 		404
Why do we need IGRT? 		405
Slide Number 5 		406
Slide Number 6 		407
Slide Number 7 		408
Slide Number 8 		409
Slide Number 9 		410
Slide Number 10 		411
Slide Number 11 		412
Rationale for IGRT 		413
Slide Number 13 		414
Imaging for treatment verification 		415
Technologies available for IGRT 		416
Technologies available for IGRT 		417
Slide Number 17 		418
Slide Number 18 		419
Slide Number 19 		420
Rationale for IGRT 		421
Slide Number 21 		422
Slide Number 22 		423
IGRT 		424
Slide Number 24 		425
Slide Number 25 		426
Slide Number 26 		427
Sources for Clinical Rationale 		428
Cites in Pubmed (2014-2016) 		429
Clinical trial, Phase III(compare new treatments with the standard) 		430
Clinical trial, Phase III 		431
COST and TIME 		432
Clinical trial, Phase II (N = 74)(if a new treatment works well) 		433
Toxicity 		434
Phase II (Prostate) 		435
Slide Number 35 		436
Slide Number 36 		437
Slide Number 37 		438
Prostate IGRT 		439
Prostate IGRT 		440
Clinical trial, Phase II (hepatocellular carcinoma ) 		441
Clinical trial, Phase II (Sarcoma) 		442
Clinical trial, Phase II (Lung) 		443
Clinical trial, Phase II (oligometastases) 		444
Clinical trial, Phase II (head and neck) 		445
Slide Number 45 		446
Adaptive radiotherapy 		447
FUTURE DIRECTIONS (phase III studies on-going) 		448
FUTURE DIRECTIONS 		449
IGRT confidence and knowledge 		450
IGRT confidence and knowledge 		451
CONCLUSIONS: Why IGRT? 		452
Slide Number 52 		453
19. Prostate_Jose Lopez 		454
Slide Number 1 		454
Outline of Talk 		455
Slide Number 3 		456
Lymph nodemetastasized prostate cancer 		457
Lymph nodemetastasized prostate cancer 		458
Lymph nodemetastasized prostate cancer 		459
Lymph nodemetastasized prostate cancer 		460
Lymph nodemetastasized prostate cancer 		461
Lymph nodemetastasized prostate cancer 		462
Slide Number 10 		463
Slide Number 11 		464
Slide Number 12 		465
Slide Number 13 		466
Slide Number 14 		467
Case 1: patient with stage N+ (D1) disease 		468
Case 1: patient with stage N+ (D1) disease 		469
Case 1: patient with stage N+ (D1) disease 		470
Slide Number 18 		471
Slide Number 19 		472
Prostate 		473
Slide Number 21 		474
Slide Number 22 		475
PTV (prostate gland+5mm margin) 		476
Seminal vesicles planning volume (orange) 		477
Pelvic lymph nodes planning volume(prophylactic [purple], positive [red]) 		478
Slide Number 26 		479
Slide Number 27 		480
20. Josipovic Prostate physicists perspective 		481
21. Prostate_MK 		500
IGRT for prostate cancer: RTT perspective 		500
Content 		501
Offline/Online bony anatomy matching 		502
Offline/Online bony anatomy matching 		503
Offline marker registration using fiducial markers 		504
Problem/challenge 		505
Fiducial markers 		506
Fiducial markers: offline 		507
Fiducial markers: offline 		508
Online fiducial marker registration 		509
Food for thought! 		510
Food for thought! 		511
Online Position Verification 		512
Offline vs Online 		513
Online Position Verification 		514
Online marker registration using CBCT 		515
ConeBeam CT: soft tissue information 		516
Many ways to Rome! 		517
The N1 case 		518
Option 1: solved by margins (AMC) 		519
Option 2: Adaptive procedure 		520
Bladder: Focal adaptive margin strategy 		521
Thank you for your attention! 		522
22. 2016_Cervix_SR 		523
Slide Number 1 		523
Cervix cancer diagnosis OMS (2002) 		524
Patient History 		525
Slide Number 5 		526
Slide Number 6 		527
Slide Number 7 		528
Slide Number 8 		529
Slide Number 9 		530
Slide Number 10 		531
Slide Number 11 		532
Slide Number 12 		533
Slide Number 13 		534
Heterogeneity in contouring target volumes besides the use of guidelines 		535
Quite good homogeneity in some OAR contouring 		536
But it’s not always the case! 		537
Upper and lower limits are a source of heterogeneity in contouring as well 		538
Take home messages:- High quality CT, MR imaging and clinical examination are crucial for contouring targets and OAR in the pelvic region- High quality re-imaging and clinical examination are key points in cervical cancer to adapt contours for brachytherapy dosimetry- MR is a key imaging modality in gynecology 		539
24. Cervix_DBN16_RdJ 		540
Slide Number 1 		540
CervixART Planselection 		541
Slide Number 3 		542
Slide Number 4 		543
Slide Number 5 		544
Slide Number 6 		545
Slide Number 7 		546
Slide Number 8 		547
Slide Number 9 		548
Slide Number 10 		549
Slide Number 11 		550
Slide Number 12 		551
Slide Number 13 		552
Slide Number 14 		553
Question 		554
Observer study setup 		555
Patient 1 		556
Patient 2 		557
Slide Number 19 		558
Result 		559
Slide Number 21 		560
Slide Number 22 		561
Slide Number 23 		562
Slide Number 24 		563
Slide Number 25 		564
Slide Number 26 		565
Slide Number 27 		566
Slide Number 28 		567
Slide Number 29 		568
Slide Number 30 		569
Slide Number 31 		570
Slide Number 32 		571
Slide Number 33 		572
Slide Number 34 		573
Slide Number 35 		574
Slide Number 36 		575
Slide Number 37 		576
Slide Number 38 		577
25. Lung_Jose Lopez 		578
Slide Number 1 		578
Slide Number 2 		579
Outline of Talk 		580
Introduction 		581
Introduction 		582
Slide Number 6 		583
Slide Number 7 		584
Recent Trials Addressing Management of Oligometastatic NSCLC 		585
Slide Number 9 		586
STEREOTACTIC ABLATIVE RADIOTHERAPY DELIVERED BY HELICAL TOMOTHERAPY FOR EXTRACRANEAL OLIGOMETASTASIS 		587
STEREOTACTIC ABLATIVE RADIOTHERAPY DELIVERED BY HELICAL TOMOTHERAPY FOR EXTRACRANEAL OLIGOMETASTASIS 		588
Slide Number 12 		589
Slide Number 13 		590
Slide Number 14 		591
Slide Number 15 		592
Slide Number 16 		593
Slide Number 17 		594
Slide Number 18 		595
Case 1: Oligorecurrence of lung cancer 		596
Slide Number 20 		597
Slide Number 21 		598
Slide Number 22 		599
Motion artifacts are commonly seen with thoracic CT images 		600
Motion artifacts 		601
Tumor movement 		602
Slide Number 26 		603
Slide Number 27 		604
Slide Number 28 		605
26. Josipovic Lung physicists perspective 		606
27. Lung_MK 		626
Lung SBRT on the linac 		626
Key features SBRT 		627
What do we have to manage? 		628
Intra fraction motion: amplitude 		629
Inter fraction motion: baseline shift 		630
Baseline shift 		631
Slide Number 7 		632
Slide Number 8 		633
Managing intra fraction motion 		634
Management of baseline shifts 		635
Option 1: NKI/ELEKTA solution 		636
Option 1: NKI/ELEKTA solution 		637
Option 2: critical isodose 		638
Option 3: homemade excel sheet 		639
Reference CT: OAR ROI (Clipbox) 		640
Reference CT: Tumor ROI (Mask) 		641
Step 1: image registration on OAR 		642
Step 2: image registration on tumor 		643
Verify the registration 		644
Slide Number 20 		645
Convert to correction 		646
Registration data in overview tab 		647
Fill in data in excel sheet 		648
Perform table correction and 2nd CBCT 		649
Fill in data of 2nd CBCT in excel sheet 		650
Starting treatment? 		651
Slide Number 27 		652
Thank you for your attention! 		653
28. Breast_2SR_clean 		654
Slide Number 1 		654
Clinical case 		655
Mammograms + US 		656
Angio mammography 		657
Breast MRI 		658
Clinical case 		659
Therapeutic strategy: Which radiotherapy? 		660
Slide Number 8 		661
Slide Number 9 		662
Partial breast irradiation indication guidelines 		663
Intraoperative Partial breast versus whole breast irradiation 		664
Slide Number 12 		665
EBRT allows for conformal treatment 		666
Slide Number 14 		667
PAPBI: first résults 		668
Dosimetry 		669
Dosimetry 		670
Dosimetric comparision between APBI 		671
Re-positionning control 		672
Heart Toxicity 		673
Cardiac risk is increased by cardiovascular risk factors 		674
Improved heart sparing by breath hold 		675
How to improve heart sparing? 		676
Take home messages:- Accelerated hypofractionated whole breast and partial breast irradiation are changing our practices for early breast cancers with good prognosis factors- Contouring and positioning remain key points for these treatment strategies- Moving toward better sparing OAR means we need to assess low dose consequences as well 		677
30. Breast RTT Perspective 2016 		678
32. Forde_Varian CBCT 2016 		705
33. WorkshopImageRegistrationElekta_DBN16 		771
‘steps’of registration @AMC 		771
Reference settings – 1x 		772
Image registration and evaluation 		773
Image registration and evaluation 		774
Image registration and evaluation 		775
Symantics @Elekta 		776
Slide Number 7 		777
Slide Number 8 		778
Slide Number 9 		779
Algorithms @Elekta 		780
Algorithms 		781
Slide Number 12 		782
Slide Number 13 		783
Bone and seed algoritme 		784
Bone and seed algoritme 		785
Algoritmes 		786
Cons:Local minima: specifically a problem for small regions of interest depending on cost function 		787
Slide Number 18 		788
Slide Number 19 		789
CRP @Elekta 		790
Correction Reference Point 		791
Correction Reference Point 		792
Correction Reference Point 		793
Correction Reference Point 		794
Correction Reference Point 		795
Slide Number 26 		796
Slide Number 27 		797
Slide Number 28 		798
34. Head&neck_SR 		799
Slide Number 1 		799
Changing traditional scenario in H&N cancer 		800
Patient history 		801
Clinical examination 		802
Slide Number 5 		803
Slide Number 6 		804
Slide Number 7 		805
Slide Number 8 		806
Slide Number 9 		807
Slide Number 10 		808
Slide Number 11 		809
Slide Number 12 		810
Slide Number 13 		811
Slide Number 14 		812
Slide Number 15 		813
Slide Number 16 		814
Slide Number 17 		815
Slide Number 18 		816
Slide Number 19 		817
Slide Number 20 		818
Slide Number 21 		819
Slide Number 22 		820
Contouring guidelines 		821
Case used for H&N Falcon online WS 		822
Take home messages:- HPV positive tumors are changing H&N cancer traditional scenario- Positioning remain key points for these highly conformal treatments (IMRT+++)- Target and OAR contouring remains an issue: Highly heterogeneous contours- Crucial need for contouring guidelines and training 		823
36. Forde_H and N RTT Perspective 2016 		824
37. Brain_Jose Lopez 		844
Slide Number 1 		844
Outline of Talk 		845
Pearls 		846
Inmovilization 		847
Planning images 		848
Slide Number 6 		849
Slide Number 7 		850
Slide Number 8 		851
Slide Number 9 		852
Slide Number 10 		853
Technologies 		854
Slide Number 12 		855
Slide Number 13 		856
Slide Number 14 		857
Slide Number 15 		858
Slide Number 16 		859
Slide Number 17 		860
Slide Number 18 		861
BRAGG PEAK 		862
Slide Number 20 		863
Slide Number 21 		864
PTC 		865
Slide Number 23 		866
Case 1: patient with teratoid rhabdoid tumor 		867
Slide Number 25 		868
Mass at the fourth ventricle 		869
Slide Number 27 		870
Slide Number 28 		871
Slide Number 29 		872
PTV (surgical bed + 5 mm margin) 		873
PTV 		874
Slide Number 32 		875
Slide Number 33 		876
38. Josipovic Brain physicists perspective 		877
39. Brain_DBN16_RdJ 		898
Slide Number 1 		898
Brain 		899
Slide Number 3 		900
Slide Number 4 		901
Slide Number 5 		902
Slide Number 6 		903
Slide Number 7 		904
Slide Number 8 		905
Slide Number 9 		906
Slide Number 10 		907
Slide Number 11 		908
Slide Number 12 		909
Slide Number 13 		910
Slide Number 14 		911
Slide Number 15 		912
Slide Number 16 		913
Slide Number 17 		914
Slide Number 18 		915
Slide Number 19 		916
Slide Number 20 		917
Slide Number 21 		918
40. agnella2_clean 		919
Health Literacy and Cancer 		919
Slide Number 2 		920
Slide Number 3 		921
What is Literacy? 		922
Background 		923
Slide Number 6 		924
Example 		925
Consequences of Low Health Literacy 		926
Health Literacy Model 		927
Factors that Influence HL level 		928
Tools to measure HL 		929
The Newest Vital Sign-Test of Functional HL 		930
Slide Number 14 		931
Slide Number 15 		932
Same for all countries? 		933
European Health Literacy Project-HLS-EU 2009-2012 		934
European Health Literacy Project-HLS-EU 2009-2012 		935
HLS-EU ModelDomains and dimensions of Health Literacy 		936
Slide Number 21 		937
Health Literacy and Cancer 		938
HL and Radiotherapy 		939
HL and Radiotherapy 		940
HL and Radiotherapy –Ireland? 		941
HL and Radiotherapy –Ireland? 		942
Slide Number 27 		943
Slide Number 28 		944
What are the signs? 		945
Slide Number 30 		946
Can we give information better? 		947
Slide Number 32 		948
Plain Language 		949
How can we check understanding? 		950
Slide Number 35 		951
Current Study 		952
Research Aims 		953
Slide Number 44 		954
Take home message 		955
Slide Number 47 		956
41. Implementing and managing IGRT_MK 		957
Slide Number 1 		957
The Aim of the presentation 		958
Protocol implementation 		959
Preparation phase 		960
Preparation phase: Investigate! 		961
Slide Number 6 		962
Planning/protocol writing phase 		963
Implementation Phase 		964
Well described and well defined tasks 		965
Anatomical changes 		966
Slide Number 11 		967
Slide Number 12 		968
Slide Number 13 		969
Atelectases 		970
Slide Number 15 		971
Tumor regression 		972
Tumor shift 		973
Slide Number 18 		974
Rare changes 		975
Rare changes 		976
Change in lymphocele 		977
Weight loss 		978
Slide Number 23 		979
Cardiac changes 		980
Slide Number 25 		981
Summary 		982
How to deal with changing anatomy?* 		983
The protocol… 		984
Implementation Phase 		985
Plan of the day 		986
Slide Number 31 		987
Demo database ART blaas 		988
Implementation Phase 		989
Evaluation phase 		990
Bladder ART: Safety-net plan selection 		991
Conclusions 		992
Slide Number 37 		993
John Kotter’s 8 steps of change 		994
Thank you for your attention! 		995
42. WhoIsDoingWhat_DBN16_RdJ 		996
Who is doing what in Radiation Therapy 		996
Slide Number 2 		997
Survey 		998
Survey 		999
1. Indication of treatment 		1000
1. Indication of treatment 		1001
2. Pre-treatment Imaging 		1002
2. Pre treatment Imaging 		1003
3. Delineation: Target Volume 		1004
3. Delineation Target Volume 		1005
3. Delineation: Organs at Risk 		1006
3. Delineation Organs at Risk 		1007
4. Treatment Planning 		1008
4. Treatment Planning 		1009
5. Treatment Delivery 		1010
5. Treatment Delivery 		1011
6a. Image Guidance: Acquisition 		1012
6a. Image guidance: Acquisition 		1013
6b. Image Guidance: Registration 		1014
6b. Image Guidance: Registration 		1015
6c. Image Guidance: Evaluation 		1016
6c. Image Guidance: Evaluation 		1017
Who is doing what? 		1018
RTT training / Education 		1019
Training & Education 		1020
RTT training / Education 		1021
Slide Number 27 		1022
Slide Number 28 		1023
Slide Number 29 		1024
Slide Number 30 		1025
IGRT 		1026
IGRT modalities: 2D MV 		1027
IGRT modalities: 2D kV 		1028
IGRT modalities: 3D kV 		1029
IGRT modalities: 3D MV 		1030
IGRT protocols are 		1031
IGRT 		1032
IGRT 		1033
IGRT 		1034
IGRT 		1035
Who is doing ART? 		1036
Summary 		1037
Questions & Discussion 		1038
43. Safety issues and prospective risk analysis_MK 		1039
HFMEA – Martijn Kamphuis 		1039
Introduction 		1040
Failure Modes and Effects Analysis (FMEA) 		1041
FMEA project 		1042
FMEA project 		1043
Process Mapping 		1044
Slide Number 7 		1045
FMEA project 		1046
Team 		1047
FMEA project 		1048
Steps in a FMEA Process 		1049
FMEA 		1050
FMEA project 		1051
Risk Priority Number (RPN) 		1052
Example RT Process: Ford et al, 2009 		1053
Slide Number 16 		1054
Example: Step _x_ in Process: Field Placement 		1055
Example: Step _x_ in Process: Field Placement 		1056
FMEA: putting it all together 		1057
The Workshop (50 minutes) 		1058
Process map: Online 3D portal imaging 		1059
Feedback session 		1060
Conclusions 		1061
Thank you for your attention! 		1062
45. Incident management 		1063
46. WorkshopPS_DBN16_RdJ 		1097
Slide Number 1 		1097
Workshop on Plan Selection 		1098
Slide Number 3 		1099
Slide Number 4 		1100
Slide Number 5 		1101
Plan selection - cervix 		1102
Plan selection - rectum 		1103
Geometrical uncertainties rectum 		1104
Plan selection - rectum 		1105
Plan selection – rectum 		1106
Plan selection – rectum 		1107
Plan selection – rectum 		1108
Plan selection – rectum 		1109
Design of the study 		1110
Design of the study 		1111
Workflow registration and selection 		1112
Workflow registration and selection 		1113
Workflow registration and selection 		1114
Workflow registration and selection 		1115
Outcome of the study 		1116
Outcome of the study 		1117
Outcome of the study 		1118
Implementation - conclusion 		1119
Clinical protocol 		1120
Mosaiq 		1121
Administration at Linac 		1122
Safety net 		1123
Slide Number 28 		1124
Slide Number 29 		1125
Slide Number 30 		1126
Slide Number 31 		1127
Slide Number 32 		1128
Slide Number 33 		1129
Slide Number 34 		1130
Slide Number 35 		1131
ART bladder patient 1 / CBCT 1 		1132
ART bladder patient 1 / CBCT 2 		1133
ART bladder patient 1 / CBCT 3 		1134
ART bladder patient 2 / CBCT 1 		1135
ART bladder patient 2 / CBCT 2 		1136
ART bladder patient 2 / CBCT 3 		1137
Slide Number 42 		1138
Slide Number 43 		1139
Slide Number 44 		1140
Slide Number 45 		1141
Slide Number 46 		1142
Slide Number 47 		1143
Slide Number 48 		1144
Slide Number 49 		1145
ART cervix patient 1 / CBCT 1 		1146
ART cervix patient 1 / CBCT 2 		1147
ART cervix patient 1 / CBCT 3 		1148
ART cervix patient 1 / CBCT 4 		1149
ART cervix patient 2 / CBCT 1 		1150
ART cervix patient 2 / CBCT 2 		1151
ART cervix patient 3 / CBCT 3 		1152
Slide Number 57 		1153
Slide Number 58 		1154
Slide Number 59 		1155
Slide Number 60 		1156
Slide Number 61 		1157
Slide Number 62 		1158
47. AE Reporting and Role of RTT 2016 		1159
 FlippingBook